A corporate venture capital firm with global offices is looking for investments that are focused on financial returns as well as bringing strategic value to the corporate. The firm makes equity investments in seed through growth rounds ranging from €1-5M for typical investments and may invest up to €10-12M over the life of the investment. The firm will lead, co-lead or follow and typically seeks a 10-25% stake in the company. The firm is currently investing out of its second fund of €150M with a total of €350M AUM and makes 4-6 investments per year. The firm focuses on USA, Europe, and Israel-based companies.

The firm is only interested in diagnostics and monitoring devices with a particular interest in point-of-care diagnostics. Recent investments include an autonomous, mobile robot with delivery tracking software and a PCR-based diagnostic instrument for rapid pathogen detection, a connected blood glucose monitor and an enhanced PCR technology (laser PCR). The firm does not invest in traditional biopharma therapeutics and/or medical devices which require FDA approval.

The firm will work with all management teams, including first time entrepreneurs, and requires at least an observatory board seat with most investments requiring a standard board seat with voting rights.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A large USA-based venture capital firm is currently investing from its eighth fund, which raised $400 million in 2014. The firm is open to investment opportunities globally.

The firm is currently interested in novel concepts and platforms across the life sciences. The firm invests in therapeutics, devices and diagnostics, and has a lesser interest in technology-led companies in the healthcare IT space (not interested in service-based/SaaS healthcare IT businesses). The firm prefers early stage opportunities; in therapeutics, the firm focuses on pre-IND technologies. Due to the firm’s emphasis on new platforms, the firm generally does not invest in single asset companies.

While the firm invests across many areas, one focus at present is immunology assets that aim to treat infectious diseases (viral and bacterial), with a focus on immune priming or changing the immune system. Any immunological therapeutic modality is of interest, including vaccines. The firm is interested in reviewing immunology assets at any stage of development.

The firm only invests in privately held companies that have not previously raised a Series A round or a significant seed round. The firm is a highly hands-on, active investor.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A venture capital firm with offices in Europe and USA manages over $230M investing in medical technologies and healthcare IT companies with a stage agnostic strategy. The initial investment size ranges from $0.4 million for seed stage companies to $2.5 million for later stage ventures, and the firm reserves significant capital for follow on investments. The firm is primarily focused on Europe, but has also done investments in the USA and Israel.

The firm is currently looking for new investment opportunities in medical devices, diagnostics and digital health sectors. The firm has a sector focus on selected therapeutic areas including cardiovascular, neurology and oncology although the firm is opportunistic in other areas. For digital health, the firm prefers to invest in companies developing platforms, solutions and software.

The firm seeks to invest in both public and private companies and will consider pre-revenue companies.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A Hong Kong-based conglomerate has global interests in real estate development and investment, financial investment, hotels and shipping. The group continues to diversify its business and growth globally with interests in a diverse range of business partnerships, including life sciences.

The group has a global investment platform that focuses on life sciences. Leveraging on the group’s strong capital base and long-term commitment to the area, the company is aimed to become the ideal partner for scientists, entrepreneurs, corporations and investors in the life science space. Through direct investments and fund investments covering full spectrum of the industry (including therapeutics, medical devices and diagnostics) and across different development stages, the platform is starting to build significant presence in the USA and Greater China.

Within healthcare, the group looks at cutting-edge biotech therapeutic technologies across small molecule, biologics, and novel therapies. The group focuses on oncology, brain diseases, as well as drug delivery platforms and genomic diagnostics. In terms of development stages, the group focuses on pre-clinical to early clinical stage assets that are seeking series A/B/C financing.

The group looks for experienced and competent teams with sector expertise and track record of success. The firm prefers opportunities where they have already identified a healthcare-focused lead investor. The firm typically requests board representation post-investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A venture capital firm headquartered in Australia solely invests in the life sciences and generally seeks to make investments ranging from $3-10M. The firm invests globally but prefers companies with the majority of employees and assets based in Australia. The firm is a dedicated mid-stage life sciences investor, which means that the firm looks at technologies that are ready to be, or are already, trailed in humans.

The firm will invest in companies across the life science space, including therapeutics, diagnostics and medical technology. The firm does not invest in service providers. The firm considers all subsectors and indications, including orphan indications. The firm will consider technology either in or prepared for human clinical trials and is open to all classes of devices. The firm generally seeks investments in novel technology but will consider existing markets if the technology is superior.

The firm looks for companies where a large part of the technological risk has been removed, and work alongside companies to ensure that their clinical programs and other activities support their objectives and are designed to achieve the best possible outcome for the company. The firm is open to co-investments and considers public and private companies. The firm will only consider companies with granted patents or a clear patent strategy. Companies of interest must have a remote connection with Australia or the Pacific Region. This may include a facility or a partner located in the region.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A global insurance company based in Beijing, China currently has total assets under management of nearly $800 B. The firm’s investment arm has invested in several industries and is now looking for opportunities in healthcare. The firm is most interested in mature companies with stable cash flow, but it is also open to seed- and early-stage opportunities. Investment size can largely vary depending on the deal. The firm considers companies globally with a focus on North America.

The firm considers opportunistically across various sectors within healthcare, including medical devices, diagnostics, and healthcare IT, with an increased interest in senior care, wellness, wearable devices, and big data analytics. The firm prefers revenue-generating, mature businesses, while early-stage companies with proof-of-concept would also be considered. Currently, the firm is focused most on medical devices and diagnostics within the senior care space.

The firm is looking for experienced management teams with sector expertise. The firm can lead or follow in a financing round.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

An European-focused venture capital firm with partners based in Europe and USA has a current fund which is actively investing in Spain, Portugal, the UK, and Ireland. The firm is expanding into the Baltics and raising a new €100 M fund. The firm looks for companies mainly in Europe and works closely with the team to expand the business into new markets. The firm invests in Series A & B financings as a with investments ranging from €3-8 M over the life of the company. The firm is actively looking for investment opportunities and plans to make around 12 investments with the new fund over the next 4 years. The firm will only invest in private companies.

The firm is an opportunistic investor and will consider medical devices, diagnostics, and healthcare IT companies. The firm is most interested in diagnostics and healthcare IT companies as well as data- analytics and IoT companies. Previous investments include a pharmacogenetic test company and a drug delivery technology platform, clinical trial analytics and others. The firm is very opportunistic in terms of subsectors and indications. For therapeutics, the firm will only consider products that are in phase 2 stage or later. In terms of digital health, the firm has interests in consumer-facing platforms and analytics areas, such as big data-driven technologies on complex medical research.

The firm looks for management teams with highly relevant experience and strong industry knowledge is a must. The firm looks for management teams that are willing to work alongside a hands-on investor, and the firm always looks to take a board seat. The firm is open to both leading and co-investing. The firm prefers companies to be backed by strong IP protection and must have already raised seed capital.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com